SEC Form 4
Fennec Pharmaceuticals Inc. (FENC) insider trading
In the 12 months to Oct 26, 2026, 5 FENC insiders reported open-market sales of $11.3M across 10 filings; no open-market purchases were filed.
Latest filing · Last 12 months · Source: SEC EDGAR · How we count
- Open-market sales
- $11.3M
- 10 filings · 5 insiders
- Open-market purchases
- $0
- 0 filings
- Pre-arranged sales (10b5-1)
- 6 of 10
- $1.4M of $11.3M sold (13%)
Who traded FENC, and when
- Sale
- Sale, pre-arranged (10b5-1)
FENC daily close from Oct 27, 2025 to Oct 26, 2026, between $5.77 and $12.78, last $10.17. 10 sale and 0 purchase filings by 5 insiders, marked at their filing dates. John Smith Clark II, 10% owner: sold $9.7M across 3 filings, first filed Nov 17, 2025, last Dec 29, 2025. Robert Andrade, CHIEF FINANCIAL OFFICER: sold $883.5K across 1 filing, first filed Aug 28, 2026, last Aug 28, 2026. Rosty Raykov, Director → Other: sold $373.3K across 4 filings, first filed Nov 6, 2025, last Sep 1, 2026. Marco Maria Brughera, Director: sold $160.0K across 1 filing, first filed Sep 16, 2026, last Sep 16, 2026. Pierre Sargis Sayad, Chief Medical Officer: sold $146.2K across 1 filing, first filed Aug 31, 2026, last Aug 31, 2026.
Largest mark · tap a row for others
John Smith Clark II · 10% owner
Sale $7,500,000
1,000,000 shares at $7.50 avg
Filed Dec 29, 2025 · traded Dec 24
Close on filing date $7.69
John Smith Clark II · 10% owner
10% owner
$9.7M soldRobert Andrade · CHIEF FINANCIAL OFFICER
CHIEF FINANCIAL OFFICER
$883.5K soldRosty Raykov · Director → Other
Director → Other
$373.3K soldMarco Maria Brughera · Director
Director
$160.0K soldPierre Sargis Sayad · Chief Medical Officer
Chief Medical Officer
$146.2K soldOpen-market trades
10 filings in the last 12 months| Insider | Role | Sold | Bought | Filings | Pre-arranged (10b5-1) | Last filed |
|---|---|---|---|---|---|---|
| John Smith Clark II | 10% owner | $9.7M | — | 3 | — | |
| Robert Andrade | CHIEF FINANCIAL OFFICER | $883.5K | — | 1 | 100% of sales | |
| Rosty Raykov | Director → Other | $373.3K | — | 4 | 100% of sales | |
| Marco Maria Brughera | Director | $160.0K | — | 1 | 100% of sales | |
| Pierre Sargis Sayad | Chief Medical Officer | $146.2K | — | 1 | — |
| Filed | Insider | Type | Shares | Avg price | Value | Held after | Source |
|---|---|---|---|---|---|---|---|
traded | Marco Maria Brughera Director | SalePre-arranged (10b5-1) | 15,545 | $10.29 | $160.0K | 0 | |
traded | Rosty Raykov Other | SalePre-arranged (10b5-1) | 10,000 | $12.11 | $121.1K | 124,411 | |
traded | Pierre Sargis Sayad Chief Medical Officer | Sale | 12,000 | $12.18 | $146.2K | 9,519 | |
traded | Robert Andrade CHIEF FINANCIAL OFFICER | SalePre-arranged (10b5-1) | 75,000 | $11.78 | $883.5K | 217,675 | |
traded | Rosty Raykov Other | SalePre-arranged (10b5-1) | 10,000 | $9.58 | $95.8K | 131,633 | |
traded | John Smith Clark II 10% owner | Sale | 1,000,000 | $7.50 | $7.5M | 2,744,741 | |
traded | Rosty Raykov Director | SalePre-arranged (10b5-1) | 10,000 | $7.54 | $75.4K | 77,526 | |
traded | John Smith Clark II 10% owner | Sale | 19,341 | $8.79 | $170.0K | 3,744,741 | |
traded | John Smith Clark II 10% owner | Sale | 246,018 | $8.27 | $2.0M | 3,764,082 | |
traded | Rosty Raykov Director | SalePre-arranged (10b5-1) | 10,000 | $8.10 | $81.0K | 82,318 |
GET /stocks/filings/vX/form-4?tickers=FENC&filing_date.gte=2025-10-26&sort=filing_date.desc&limit=500{
"status": "OK",
"results": [
{
"tickers": [
"FENC"
],
"issuer_cik": "0001211583",
"owner_cik": "0001589776",
"accession_number": "0001589776-26-000004",
"form_type": "4",
"filing_date": "2026-09-16",
"period_of_report": "2026-09-15",
"issuer_name": "FENNEC PHARMACEUTICALS INC.",
"issuer_trading_symbol": "FENC",
"owner_name": "Brughera Marco Maria",
"is_director": true,
"is_officer": false,
"is_ten_percent_owner": false,
"is_other": false,
"security_type": "non_derivative",
"record_type": "transaction",
"security_title": "Common Shares",
"transaction_timeliness": "O",
"aff_10b5_one": true,
"transaction_date": "2026-09-15",
"transaction_code": "S",
"equity_swap_involved": false,
"transaction_shares": 15545,
"transaction_price_per_share": 10.29,
"transaction_acquired_disposed": "D",
"shares_owned_following_transaction": 0,
"transaction_value": 159958.05,
"direct_or_indirect": "D",
"footnotes": [
{
"id": "F2",
"description": "Shares sold pursuant to a 10b5-1 plan adopted on June 16, 2026."
}
]
},
{
"tickers": [
"FENC"
],
"issuer_cik": "0001211583",
"owner_cik": "0001468316",
"accession_number": "0001468316-26-000023",
"form_type": "4",
"filing_date": "2026-09-01",
"period_of_report": "2026-08-31",
"issuer_name": "FENNEC PHARMACEUTICALS INC.",
"issuer_trading_symbol": "FENC",
"owner_name": "Raykov Rosty",
"is_director": false,
"is_officer": false,
"is_ten_percent_owner": false,
"is_other": true,
"security_type": "non_derivative",
"record_type": "transaction",
"security_title": "Common shares",
"transaction_timeliness": "O",
"aff_10b5_one": true,
"transaction_date": "2026-09-01",
"transaction_code": "S",
"equity_swap_involved": false,
"transaction_shares": 10000,
"transaction_price_per_share": 12.11,
"transaction_acquired_disposed": "D",
"shares_owned_following_transaction": 124411,
"transaction_value": 121100,
"direct_or_indirect": "D",
"footnotes": [
{
"id": "F2",
"description": "Represents shares sold pursuant to a 10b5-1 plan dated September 19, 2025."
}
]
}
]
}
// trimmed to 2 resultsThe response includes every Form 4 record; this page keeps open-market purchases and sales on common stock and removes duplicate joint-filer rows.
Other insider activity (not market trades) · 92 records
- Option exercises39 records
- Tax withholding (sold to cover)8 records
- Grants and awards45 records
Reported on Form 4 but not purchases or sales in the market, so not counted in the totals above.
How to read this page
- Open-market purchase or sale
- A buy or sell of the company's stock at market price. Grants, option exercises, shares withheld for tax, gifts and employee stock plan purchases are listed separately and not counted.
- Pre-arranged (10b5-1)
- The insider marked the filing as made under a trading plan set up in advance (SEC Rule 10b5-1). The mark covers the whole filing, and an unmarked filing may still be under a plan.
- Role
- The title on each filing. Someone whose title changed shows more than one.
- Filing date
- Insiders have two business days to report a trade. Totals and the chart use the filing date, when the trade became public.
- Counted once
- When several owners (a fund and its partners, say) report the same trade, it's counted once. Corrected filings replace the originals.
Frequently asked questions
Has Fennec Pharmaceuticals Inc.'s CEO sold stock?
No. Jeffrey S. Hackman (CEO) made no open-market sales filed as CEO in the last 12 months.
How current is FENC’s insider data?
These are FENC Form 4 filings from the last year, refreshed daily. The Massive Form 4 API has the full, continuously updated record.
What counts as an open-market buy or sell?
Only purchases and sales at the market price. Option exercises, grants, gifts, and shares withheld for taxes are reported on Form 4 but are left out of the buy and sell totals.
Build with AI
Track FENC insider trades with your agent
This page joins two Massive endpoints: Form 4 filings and daily prices. Ask an agent to watch for new filings:
Using the Massive API (massive.com/docs/llms.txt), check Form 4 filings for FENC every day with transaction_code=P and tell me when an insider files an open-market purchase, with their role, shares, price and the filing link.
Nothing on this page is investment advice. All data and content is provided for informational purposes under our Terms of Service.